Drug Trial Radar · NCT05244551
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
85
Planned (sponsor's estimate)
Start
Jun 30, 2022
Primary completion
Apr 30, 2025
Study completion Apr 30, 2025
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Conditions
- Solid Tumor
Interventions
ABSK061Drug
In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Incidence and severity of adverse events (AEs)Time frame: Through study completion, an average of half year
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
Yuan LU
Shanghai, Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515, China · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Not yet recruiting
Chongqing Daping Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Gongshu District, China · Recruiting
Sun Yat-sen Memorial Hospital/ the Second Affiliated Hospital of Sun Yat-sen University
Guanzhou, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China · Not yet recruiting
Xuzhou Center Hospital
Xuzhou, Jiangsu, China · Recruiting
First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
JILIN Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
Yunnan Cancer Hospital
Yunnan, Kunming, China · Not yet recruiting
Liaoning Province Cancer Hospital
Shenyang, Liaoning, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, Sichuan, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hanzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.